Supraophthalmic intracarotid infusion of bcnu for malignant glioma

Sun Hoo Foo, In Sup Choi, Alejandro Berenstein, Arlene Wise, Joseph Ransohoff, Maxim Koslow, Ajax George, Jokph Lin, Irwin Feigin, Gleb Budzilovich, Mark Kupersmith, Richard Hanson, Steve Lequerica, Slobodan Aleksic, Irvin Kricheff

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


We treated five patients with 11 supraophthalmic infusions of BCNU at 200 mg/m2 every 2 months. All three patients with residual tumors showed marked CT response after one infusion. Two patients with bilateral tumors had no response on the contralateral side. All four evaluable cases showed evidence of BCNU neurotoxicity. CT findings superficially resembled tumor recurrence, but white matter changes, nonspecific gyral enhancement, and delayed calcification were more indicative of neurotoxicity. There were no procedure-related complications. One autopsy suggested that direct parenchymal damage might be responsible for delayed neurotoxicity. Supraophthalmic BCNU infusion, at this dosage, is too toxic for cerebral tissue.

Original languageEnglish
Pages (from-to)1437-1444
Number of pages8
Issue number11
StatePublished - Nov 1986
Externally publishedYes


Dive into the research topics of 'Supraophthalmic intracarotid infusion of bcnu for malignant glioma'. Together they form a unique fingerprint.

Cite this